Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double‐blind, placebo‐controlled Phase 2 trial

Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double‐blind, placebo‐controlled Phase 2 trial

Abstract Background In patients with atopic dermatitis (AD), Staphylococcus aureus frequently colonizes lesions and is hypothesized to be linked to disease severity and progression. Treatments that reduce S. aureus colonization without significantly affecting the skin commensal microbiota are needed...

Full description

Bibliographic Details
Main Authors: Anne Weiss, Emilie Delavenne, Carina Matias, Heimo Lagler, Daniel Simon, Ping Li, Jon U. Hansen, Teresa Pires dosSantos, Bimal Jana, Petra Priemel, Christine Bangert, Martin Bauer, Sabine Eberl, Alina Nussbaumer‐Pröll, Zoe Anne Österreicher, Peter Matzneller, Tamara Quint, Maria Weber, Hanne Mørck Nielsen, Thomas Rades, Helle Krogh Johansen, Henrik Westh, Wooseong Kim, Eleftherios Mylonakis, Christian Friis, Luca Guardabassi, John Pace, Carina Vingsbo Lundberg, Fatima M'Zali, Pascal Butty, Nikolaj Sørensen, Henrik Bjørn Nielsen, Rasmus Toft‐Kehler, Emma Guttman‐Yassky, Georg Stingl, Markus Zeitlinger, Morten Sommer
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:Clinical and Translational Medicine
Subjects:
bench‐to‐bedside
dermatology
microbiome
small molecule
Online Access:https://doi.org/10.1002/ctm2.790

Internet

https://doi.org/10.1002/ctm2.790

Similar Items